Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
Covered drugs include Wegovy, Zepbound (KwikPen only), and Foundayo
Conclusions This study represents the largest cohort to date showing that GLP-1 RAs use in KTRs with T2DM is associated with reduced risks of mortality, as well as adverse cardiovascular and kidney outcomes, compared to nonuse
Supports Cardiovascular System
In March 2025, Roche entered into an outstanding licensing agreement and collaboration with Zealand Pharma for co-commercializing and co-developing petrelintide as a standalone therapy and a fixed-dose combination with Roches lead incretin asset CT-388
US$ 23.63
US$ 20.85
US$ 28.25
